Literature DB >> 7827936

Groin dissection in malignant melanoma.

C P Karakousis1, D L Driscoll.   

Abstract

A total of 205 patients who underwent groin dissection for malignant melanoma were reviewed to document complications and survival rates. Wound complications included skin-edge necrosis in 8 per cent, wound infection in 16 per cent, lymphocele in 5 per cent and lymphorrhoea in 11 per cent. Lymphoedema of the operated leg below the knee was noted in 40 per cent, but all patients had localized oedema of the anteromedial thigh. The 5-year overall and disease-free survival rates were 43 and 35 per cent respectively when only the inguinal nodes were involved; they were 34 and 21 per cent with involvement of both the inguinal and deep nodes. The 10-year survival rate for these two groups was 39 and 25 per cent respectively, which suggests that a thorough, complete dissection of the deep nodes is worth-while when the inguinal nodes are palpably positive.

Entities:  

Mesh:

Year:  1994        PMID: 7827936     DOI: 10.1002/bjs.1800811221

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  15 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

2.  Sarcomas in the groin and inguinal canal--often missed and difficult to manage.

Authors:  T Collin; A V Blackburn; R H Milner; C Gerrand; M Ragbir
Journal:  Ann R Coll Surg Engl       Date:  2010-05       Impact factor: 1.891

3.  Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.

Authors:  Sharon B Chang; Robert L Askew; Yan Xing; Storm Weaver; Jeffrey E Gershenwald; Jeffrey E Lee; Richard Royal; Anthony Lucci; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

4.  Groin lymphadenectomy with preservation of femoral fascia: total inguinofemoral node dissection for treatment of vulvar carcinoma.

Authors:  Leonardo Micheletti; Fabrizio Bogliatto; Marco Massobrio
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

5.  Laparoscopic iliac and iliofemoral lymph node resection for melanoma.

Authors:  Don Hoang; Kurt E Roberts; Edward Teng; Deepak Narayan
Journal:  Surg Endosc       Date:  2012-08-12       Impact factor: 4.584

6.  Weight lifting in patients with lower-extremity lymphedema secondary to cancer: a pilot and feasibility study.

Authors:  Elana Katz; Nicole L Dugan; Joy C Cohn; Christina Chu; Rebecca G Smith; Kathryn H Schmitz
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

7.  Wound complications after inguinal lymph node dissection for melanoma: is ACS NSQIP adequate?

Authors:  Carly E Glarner; David Y Greenblatt; Robert J Rettammel; Heather B Neuman; Sharon M Weber
Journal:  Ann Surg Oncol       Date:  2013-01-22       Impact factor: 5.344

8.  Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection.

Authors:  A P T van der Ploeg; A C J van Akkooi; P I M Schmitz; A N van Geel; J H de Wilt; A M M Eggermont; C Verhoef
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

9.  Risk factors for short- and long-term complications after groin surgery in vulvar cancer.

Authors:  F Hinten; L C G van den Einden; J C M Hendriks; A G J van der Zee; J Bulten; L F A G Massuger; H P van de Nieuwenhof; J A de Hullu
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

10.  Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma.

Authors:  Mattijs de Vries; Harald J Hoekstra; Josette E H M Hoekstra-Weebers
Journal:  Ann Surg Oncol       Date:  2009-07-29       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.